Increased serum concentration of apolipoprotein B is associated with an increased risk of reaching renal replacement therapy in patients with diabetic kidney disease

References

• Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health. 2008;8:117.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012; 379:815–822.
   PubMed Web of Science ®Google Scholar
• Kaysen GA. New insights into lipid metabolism in chronic kidney disease. J Ren Nutr. 2011;21:120–123.
   PubMed Web of Science ®Google Scholar
• Bobulescu IA. Renal lipid metabolism and lipotoxicity. Curr Opin Nephrol Hypertens. 2010;19:393–402.
   PubMed Web of Science ®Google Scholar
• Ruan XZ, Varghese Z, Moorhead JF. An update on the lipid nephrotoxicity hypothesis. Nat Rev Nephrol. 2009;5:713–721.
   PubMed Web of Science ®Google Scholar
• Vaziri ND. Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease. Clin Exp Nephrol. 2014;18:265–268.
   PubMed Web of Science ®Google Scholar
• Florens N, Calzada C, Lyasko E, et al. Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins. Toxins (Basel). 2016;8:376.
   PubMed Web of Science ®Google Scholar
• Mikolasevic I, Žutelija M, Mavrinac V, et al. Dyslipidemia in patients with chronic kidney disease: etiology and management. Int J Nephrol Renovasc Dis. 2017;10:35–45.
   PubMed Web of Science ®Google Scholar
• Chan DT, Dogra GK, Irish AB, et al. Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III. J Lipid Res. 2009;50:2524–2531.
   PubMed Web of Science ®Google Scholar
• Kaysen GA. Lipid and lipoprotein metabolism in chronic kidney disease. J Ren Nutr. 2009;19:73–77.
   PubMed Web of Science ®Google Scholar
• Kasiske BL, O'Donnell MP, Cleary MP, et al. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int. 1988;33:667–672.
   PubMed Web of Science ®Google Scholar
• Kasiske BL, O'Donnell MP, Keane WF. The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension. 1992;19:I110–I115.
   PubMed Web of Science ®Google Scholar
• Attman PO, Samuelsson O, Alaupovic P. Progression of renal failure: role of apolipoprotein B-containing lipoproteins. Kidney Int Suppl. 1997;63:S98–S101.
   PubMedGoogle Scholar
• Samuelsson O, Aurell M, Knight-Gibson C, et al. Apolipoprotein-B-containing lipoproteins and the progression of renal insufficiency. Nephron. 1993; 63:279–285.
   PubMed Web of Science ®Google Scholar
• Samuelsson O, Mulec H, Knight-Gibson C, et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant. 1997;12:1908–1915.
   PubMed Web of Science ®Google Scholar
• Schaeffner ES, Kurth T, Curhan GC, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003;14:2084–2091.
   PubMed Web of Science ®Google Scholar
• Rahman M, Yang W, Akkina S, et al.; CRIC Study Investigators. Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study. Clin J Am Soc Nephrol. 2014;9:1190–1198.
   PubMed Web of Science ®Google Scholar
• Bae JC, Han JM, Kwon S, et al. LDL-C/apoB and HDL-C/apoA-1 ratios predict incident chronic kidney disease in a large apparently healthy cohort. Atherosclerosis. 2016;251:170–176.
   PubMed Web of Science ®Google Scholar
• Zhang H, Shi S, Zhao XJ, et al. Association between the lipid profile and renal dysfunction in the heart failure patients. Kidney Blood Press Res. 2019;44:52–61.
   PubMed Web of Science ®Google Scholar
• Dalrymple LS, Kaysen GA. The effect of lipoproteins on the development and progression of renal disease. Am J Nephrol. 2008;28:723–731.
   PubMed Web of Science ®Google Scholar
• Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2000;23:S4–S19.
   PubMed Web of Science ®Google Scholar
• KDOQI. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49:S12–S154.
   PubMed Web of Science ®Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Papageorgiou AA, Elisaf M, GREACE Study Collaborative Group, et al. Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin. 2003;19:615–617.
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, et al.; CARDS Investigators. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis. 2009;54:810–819.
   PubMed Web of Science ®Google Scholar
• Stock J. Triglycerides and cardiovascular risk: apolipoprotein B holds the key. Atherosclerosis. 2019;284:221–222.
   PubMed Web of Science ®Google Scholar
• Trompet S, Packard CJ, Jukema JW. Plasma apolipoprotein-B is an important risk factor for cardiovascular disease, and its assessment should be routine clinical practice. Curr Opin Lipidol. 2018;29:51–52.
   PubMed Web of Science ®Google Scholar
• Sato H, Suzuki S, Kobayashi H, et al. Immunohistological localization of apolipoproteins in the glomeruli in renal disease: specifically apoB and apoE. Clin Nephrol. 1991;36:127–133.
   PubMed Web of Science ®Google Scholar
• Hegele RA, Harris SB, Zinman B, et al. Increased plasma apolipoprotein B-containing lipoproteins associated with increased urinary albumin within the microalbuminuria range in type 2 diabetes. Clin Biochem. 1999;32:143–148.
   PubMed Web of Science ®Google Scholar
• Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007;116:1832–1844.
   PubMed Web of Science ®Google Scholar